# Dare Bioscience, Inc. (DARE) · Edgar & Edgarette company card

> Dare Bioscience (DARE) grew revenue 10429% in FY2025 to $1 million, operating margin -1316% against a -3.8% median for pharmaceutical preparations, equity 8.8% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1401914 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/DARE) · [JSON](https://www.pops4.com/boards/company/DARE.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $1M |
| Revenue growth, 1 year | 10429.4% |
| Revenue growth per year | — |
| Operating margin | -1315.5% (prior year -239692.2%) |
| Net margin | -1300.7% |
| Operating cash flow | −$10M |
| Capital spending | $385,278 |
| Free cash flow | −$10M |
| Cash | $25M |
| Long-term debt | — |
| Total assets | $32M |
| Total equity | $3M |
| Equity ÷ assets | 8.8% |
| Return on equity | -471.4% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -20.96 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -1315.5% in FY2025; revenue is hard to predict: its 80% range is ±53%

## Edgarette's reading

Exposure: revenue $1.0M (FY2025). Experience: revenue up 10429.4% on the year; operating margin -1315.5%, up from -239692.2%. Soundness: equity 8.8% of assets, return on equity -471.4%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $29.8M and $96.1M next year (method v4.1: its own 1-year record of growth weighed at 0% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $27.5M to $104.4M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -1315.5% against a -3.8% median; growth 10429.4% against 13.7%.

Range logged 2026-09-24, receipt 375bc70851a2672a, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-10-02 ([filing](https://www.sec.gov/Archives/edgar/data/1401914/000140191426000052/0001401914-26-000052-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-06-12 ([filing](https://www.sec.gov/Archives/edgar/data/1401914/000140191426000032/0001401914-26-000032-index.htm))

## Recent filings

- DEF 14A · filed 2026-10-06 · [filing](https://www.sec.gov/Archives/edgar/data/1401914/000149315226045977/0001493152-26-045977-index.htm)
- 8-K · filed 2026-10-02 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule · [filing](https://www.sec.gov/Archives/edgar/data/1401914/000140191426000052/0001401914-26-000052-index.htm)
- 8-K · filed 2026-10-01 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1401914/000149315226045275/0001493152-26-045275-index.htm)
- 8-K · filed 2026-09-11 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year · [filing](https://www.sec.gov/Archives/edgar/data/1401914/000140191426000050/0001401914-26-000050-index.htm)
- 8-K · filed 2026-09-09 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1401914/000149315226041904/0001493152-26-041904-index.htm)
- S-1 · filed 2026-08-26 · [filing](https://www.sec.gov/Archives/edgar/data/1401914/000149315226040265/0001493152-26-040265-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001401914.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1401914

## Cite

POPS4, Edgar & Edgarette: Dare Bioscience, Inc. (DARE) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/DARE. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.